Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | IGF1R | P08069 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.32 |
| ▸ | FLT4 | P35916 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | FLT3 | P36888 | 1/20 | 0.32 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.32 |
| ▸ | TEK | Q02763 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24344421 | 1.00 | EGFR (0.32) | EGFRIGF1RSRCFLT4KDR | |
| SCHEMBL29534674 | 0.88 | DGAT1 (0.33) | DGAT1 | |
| SCHEMBL24344846 | 0.88 | DGAT1 (0.33) | DGAT1 | |
| SCHEMBL27251338 | 0.84 | BRD4 (0.33) | DGAT1 | |
| SCHEMBL29513827 | 0.84 | BRD4 (0.31) | DGAT1 | |
| SCHEMBL25345302 | 0.84 | BRD4 (0.31) | DGAT1 | |
| SCHEMBL25347436 | 0.77 | UCHL1 (0.36) | — | |
| SCHEMBL24344853 | 0.77 | EGFR (0.34) | EGFRIGF1RSRCFLT4KDR | |
| SCHEMBL25346428 | 0.77 | — | — | |
| SCHEMBL1271939 | 0.76 | IRAK4 (0.34) | EGFRDGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4225742-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | Enliven Therapeutics, Inc. (US) | 2023-08-16 | — | — | EP | disclosed |
| WO-2022076975-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN THERAPEUTICS, INC. (US) | 2022-04-14 | — | — | WO | disclosed |